BCAT2 and bladder transitional cell carcinoma: Although there was no significant difference on overall survival (OS) between high and low BCAT2 groups in desert type of IMvigor210 cohort, prognosis tendency still similar with the outcome of Xiangya BLCA immunotherapy cohort (Figure 7I).